Abstract
The 2-pyridones are a new class of broad-spectrum orally bioavailable antibacterial agents. These compounds are potent bacterial DNA gyrase inhibitors which differ from fluoroquinolones by placement of the nitrogen atom in the ring juncture. ABT-719 is an S isomer and a representative 2-pyridone. ABT-719 administered orally or subcutaneously was 4- to 10-fold more effective than ciprofloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes infections in normal mice. ABT-719 was equivalent in efficacy to ciprofloxacin for treatment of gram-negative bacterial infections caused by Pseudomonas aeruginosa or Escherichia coli. The racemate and R forms of ABT-719 produced similar results against gram-positive and gram-negative bacterial infections. The 50% effective doses of ABT-719 were at least threefold lower than those of ciprofloxacin for therapy of intracellular infections caused by Salmonella typhimurium or Listeria monocytogenes. In immunosuppressed mice, ABT-719 was more effective than ciprofloxacin against quinolone-sensitive S. aureus, Enterococcus faecalis, and Enterococcus faecium. The pharmacokinetic properties of ABT-719 were consistent with its relative efficacy. The 2-pyridones are potent, orally available antibacterial agents with efficacy against gram-positive and gram-negative bacterial infections in mice.
Full Text
The Full Text of this article is available as a PDF (223.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azoulay-Dupuis E., Bedos J. P., Vallée E., Pocidalo J. J. Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. J Antimicrob Chemother. 1991 Dec;28 (Suppl 100):45–53. doi: 10.1093/jac/28.suppl_c.45. [DOI] [PubMed] [Google Scholar]
- Barry A. L., Fuchs P. C. Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin. J Antimicrob Chemother. 1991 Nov;28(5):695–699. doi: 10.1093/jac/28.5.695. [DOI] [PubMed] [Google Scholar]
- Clement J. J., Tanaka S. K., Alder J., Vojtko C., Beyer J., Hensey D., Ramer N., McDaniel D., Chu D. T. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob Agents Chemother. 1994 May;38(5):1071–1078. doi: 10.1128/aac.38.5.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fernandez-Guerrero M., Rouse M. S., Henry N. K., Geraci J. E., Wilson W. R. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother. 1987 Mar;31(3):430–433. doi: 10.1128/aac.31.3.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gentry L. O. Review of quinolones in the treatment of infections of the skin and skin structure. J Antimicrob Chemother. 1991 Dec;28 (Suppl 100):97–110. doi: 10.1093/jac/28.suppl_c.97. [DOI] [PubMed] [Google Scholar]
- Gentry L. O., Rodriguez G. G. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother. 1990 Jan;34(1):40–43. doi: 10.1128/aac.34.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goetz M. B., Mulligan M. E., Kwok R., O'Brien H., Caballes C., Garcia J. P. Management and epidemiologic analyses of an outbreak due to methicillin-resistant Staphylococcus aureus. Am J Med. 1992 Jun;92(6):607–614. doi: 10.1016/0002-9343(92)90778-a. [DOI] [PubMed] [Google Scholar]
- Hardy D. J., Swanson R. N., Hensey D. M., Ramer N. R., Bower R. R., Hanson C. W., Chu D. T., Fernandes P. B. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987 Nov;31(11):1768–1774. doi: 10.1128/aac.31.11.1768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hooper D. C., Wolfson J. S. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991 Feb 7;324(6):384–394. doi: 10.1056/NEJM199102073240606. [DOI] [PubMed] [Google Scholar]
- Ingerman M., Pitsakis P. G., Rosenberg A., Hessen M. T., Abrutyn E., Murray B. E., Levison M. E. beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis. J Infect Dis. 1987 Jun;155(6):1226–1232. doi: 10.1093/infdis/155.6.1226. [DOI] [PubMed] [Google Scholar]
- Jones R. N. Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians? Diagn Microbiol Infect Dis. 1992 Feb;15(2):177–179. doi: 10.1016/0732-8893(92)90046-v. [DOI] [PubMed] [Google Scholar]
- Ling J. M., Lam A. W., Cheng A. F., French G. L. Activity of beta-lactam antibiotics in an animal model against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1993 Dec;32(6):919–920. doi: 10.1093/jac/32.6.919. [DOI] [PubMed] [Google Scholar]
- Neu H. C. Clinical use of the quinolones. Lancet. 1987 Dec 5;2(8571):1319–1322. doi: 10.1016/s0140-6736(87)91205-0. [DOI] [PubMed] [Google Scholar]
- Swanson R. N., Hardy D. J., Chu D. T., Shipkowitz N. L., Clement J. J. Activity of temafloxacin against respiratory pathogens. Antimicrob Agents Chemother. 1991 Mar;35(3):423–429. doi: 10.1128/aac.35.3.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thys J. P., Jacobs F., Motte S. Quinolones in the treatment of lower respiratory tract infections. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1212–S1219. doi: 10.1093/clinids/11.supplement_5.s1212. [DOI] [PubMed] [Google Scholar]
- Trucksis M., Hooper D. C., Wolfson J. S. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann Intern Med. 1991 Mar 1;114(5):424–426. doi: 10.7326/0003-4819-114-5-424. [DOI] [PubMed] [Google Scholar]